Journal article

Acute ischemic stroke Imaging-guided tenecteplase treatment in an extended time window

MW Parsons, F Miteff, GA Bateman, N Spratt, A Loiselle, J Attia, CR Levi

NEUROLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2009

Abstract

BACKGROUND: Tenecteplase is a modified tissue plasminogen activator with a longer half-life and higher fibrin specificity than alteplase. METHODS: We conducted a prospective, nonrandomized, pilot study of 0.1 mg/kg IV tenecteplase given 3 to 6 hours after ischemic stroke onset. For a control group, we used patients contemporaneously treated with sub-3-hour 0.9 mg/kg IV alteplase following standard selection criteria. All patients underwent pretreatment and 24-hour perfusion/angiographic imaging with CT or MRI. Eligibility criteria for tenecteplase (but not alteplase) treatment included a perfusion lesion at least 20% greater than the infarct core, with an associated vessel occlusion. Primary..

View full abstract